DRUGS & SUPPLEMENTS
Warnings and Precautions, Central Nervous System Effects (5.5) 07/2015
1 INDICATIONS AND USAGE
Dridase 3% (oxybutynin) gel 3% is a muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see Clinical Studies (14) ].
Dridase 3% is a muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)
2 DOSAGE AND ADMINISTRATION
The recommended dosage is three pumps of Dridase 3% (84 mg/day) applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs. Apply immediately after actuating the dose. Application sites may be rotated to reduce the potential for local site reactions [see Adverse Reactions (6.1) ]. Dridase 3% is for topical application only and should not be ingested.
Wash hands immediately after product application. Patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated [see Warnings and Precautions (5.3) ].
3 DOSAGE FORMS AND STRENGTHS
Dridase 3% is a homogeneous, colorless to slightly colored gel 3%.
Gel; 3% (3)
The use of Dridase 3% is contraindicated in patients with the following conditions:
5 WARNINGS AND PRECAUTIONS
5.1 Urinary Retention
Use Dridase 3% with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.
5.2 Use in Patients with Gastrointestinal Disorders
Use Dridase 3% with caution in patients with gastrointestinal obstructive disorders because of the risk of gastric retention.
Dridase 3%, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis or intestinal atony.
Dridase 3% should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs that can cause or exacerbate esophagitis.
5.3 Skin Transference
Transfer of Dridase to another person can occur when vigorous bare skin-to-skin contact is made with the application site. To minimize the potential transfer of Dridase from treated skin to another person, patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated [see Clinical Pharmacology (12.3) ]. Patients should wash their hands immediately after application of Dridase 3%.
5.4 Flammable Gel
Dridase 3% is an alcohol-based gel and is therefore flammable. Avoid open fire or smoking until gel has dried.
5.5 Central Nervous System Effects
Drugs containing Dridase are associated with anticholinergic central nervous system effects. A variety of CNS anticholinergic effects have been reported, including headache, dizziness, somnolence, confusion and hallucinations . Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment. Advise patients not to drive or operate heavy machinery until they know how Dridase 3% affects them. If a patient experiences anticholinergic CNS effects, drug discontinuation should be considered.
5.6 Myasthenia Gravis
Administer Dridase 3% with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.
Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral Dridase. In the event of angioedema, Dridase containing product should be discontinued and appropriate therapy promptly provided.
5.8 Controlled Narrow-Angle Glaucoma
Administer Dridase 3% with caution in patients being treated for narrow-angle glaucoma.
6 ADVERSE REACTIONS
Most common adverse reactions are dry mouth, and application site reactions. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.
The safety of Dridase 3% was evaluated in 626 patients (210 randomized to Dridase 3% 56 mg/day, 214 randomized to Dridase 3% 84 mg/day and 202 randomized to placebo) during a randomized, placebo-controlled, double-blind, 12-week clinical efficacy and safety study. A subset of these 626 patients (N = 77) participated in the 24-week open-label safety extension that followed the placebo-controlled study. Of the 77 patients in the safety extension, 24 were randomized to placebo gel during the double-blind, placebo-controlled 12-week study. In the combined double-blind, placebo-controlled study and the open-label safety extension, a total of 441 patients were exposed to at least one dose of Dridase 3%. 364 patients received at least 12 weeks of Dridase 3% treatment and 66 patients received an additional 24 weeks of Dridase 3% treatment during the open-label safety extension. The study population primarily consisted of women (87%) of Caucasian descent (87%) with an average age of 59 years who had overactive bladder with urge urinary incontinence.
Table 1 lists adverse reactions (ARs), regardless of causality, that were reported in the randomized, double-blind, placebo-controlled 12-week study at an incidence greater than placebo and in greater than 3% of patients treated with Dridase 3%.
Overall, 672 ARs were experienced by 51.9% of patients. Majority of the ARs were mild to moderate in intensity. The AR most commonly reported was dry mouth which was experienced by a greater proportion of patients in the Dridase group than the placebo group (26 patients [12.1%] in the Dridase 84 mg group, 10 patients [5.0%] in the placebo group). Application site erythema was the next most commonly reported AR (8 patients [3.7%] in the Dridase 84 mg group and 2 patients [1.0%] in the placebo group). Other commonly reported ARs experienced by more patients in the Dridase groups compared with placebo were application site rash (7 patients [3.3%] in the Dridase 84 mg group and 1 patient [0.5%] in the placebo group); application site pruritus (6 patients [2.8%] in the Dridase 84 mg group and 1 patient [0.5%] in the placebo group). The overall rate of application site adverse reactions of any kind was 14.2% in patients receiving Dridase 3% as compared to 3.7% in patients receiving placebo. Other cholinergic AEs < 2% in occurrence include dry eyes and blurred vision.
There were no deaths during the study. There were no clinically meaningful changes in vital signs, laboratory values, or ECG examinations over the course of the study.
* Each patient is counted only once within each treatment, body system and preferred term. All percentages are based on number of patients in the ITT population within each treatment group as denominator.
During the 24-week open-label safety extension, the most commonly reported ARs were urinary tract infection and nasopharyngitis reported in 4 patients each (5.2%), followed by conjunctivitis and application site erythema (both occurred in 3 patients [3.9%]). One patient prematurely discontinued due to the application site erythema and pruritus (both considered to be of mild severity).
6. 2 Po s t m a r k e t ing E x perie n ce
The following adverse reactions have been identified during post approval use of GELNIQUE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Nervous System Disorders: dizziness, somnolence, confusion
Psychiatric Disorders: hallucinations
7 DRUG INTERACTIONS
No specific drug-drug interaction studies have been performed with Dridase 3%.
7.1 Other Anticholinergics
The concomitant use of Dridase 3% with other anticholinergic (antimuscarinic) agents may increase the frequency and/or severity of dry mouth, blurred vision, and other anticholinergic pharmacological effects.
8 USE IN SPECIFIC POPULATIONS
Pregnancy Category B.
There are no adequate and well-controlled studies of topical or oral Dridase use in pregnant women. Reproduction studies using Dridase chloride in the hamster, rabbit, rat, and mouse have shown no evidence of impaired fertility or harm to the fetus. The safety of Dridase 3% administration to women who are or who may become pregnant has not been established. Therefore, Dridase 3% should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards.
8.2 Labor and Delivery
Dridase 3% has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.
8.3 Nursing Mothers
It is not known whether Dridase is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Dridase 3% is administered to a nursing woman.
8.4 Pediatric Use
The safety and effectiveness of Dridase 3% have not been established in pediatric patients.
8.5 Geriatric Use
Of the 424 patients exposed to Dridase 3% in the randomized, double-blind, placebo-controlled 12-week study, 182 patients were 65 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients.
8.6 Renal Impairment
Patients with renal impairment received Dridase 3% during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without impaired renal function.
8.7 Hepatic Impairment
Patients with hepatic impairment received Dridase 3% during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without impaired hepatic function.
Overdosage with Dridase has been associated with anticholinergic effects including central nervous system excitation, flushing, fever, dehydration, cardiac arrhythmia, vomiting, exhaustion, heat sensitivity, and urinary retention. Oral ingestion of 100 mg Dridase chloride in association with alcohol has been reported in a 13-year-old who experienced memory loss, and in a 34-year-old who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine. Both patients recovered fully with symptomatic treatment. If overexposure occurs, monitor patients until symptoms resolve.
Dridase is an antispasmodic, antimuscarinic agent. Dridase 3% is a topical, homogeneous, very lightly to moderately opalescent, translucent colorless to slightly colored gel, without particles. The product is a hydroalcoholic gel containing 30 mg Dridase per gram of gel. Dridase 3% is available in a 0.92 gram (1 mL) unit dose that contains 28 mg Dridase. Dridase is delivered as a racemate of R- and S-isomers. Chemically, Dridase base is d, l (racemic) 4-(Diethylamino)-2-butynyl (±)-α-phenylcyclohexaneglycolate.
The empirical formula of Dridase base is C22H31NO3. Its structural formula is:
Dridase is widely distributed in body tissues following systemic absorption. The volume of distribution was estimated to be 193 L after intravenous administration of 5 mg Dridase chloride.
Dridase is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Metabolites include N-desethyloxybutynin (DEO), which is pharmacologically active and phenylcyclohexylglycolic acid, which is pharmacologically inactive.
Transdermal administration of Dridase bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyloxybutynin metabolite. Only small amounts of CYP3A4 are found in skin, limiting pre-systemic metabolism during transdermal absorption. The AUC ratio of N-desethyloxybutynin metabolite to parent compound following multiple transdermal applications is approximately 1:1 for Dridase 3%. The apparent half-life was approximately 30 hours.
Dridase undergoes extensive hepatic metabolism, with less than 0.1% of the administered dose excreted unchanged in the urine. Less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
The potential for dermal transfer of Dridase from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with Dridase 3% engaged in vigorous contact with an untreated partner for 15 minutes, either with (N = 14 couples) or without (N = 14 couples) clothing covering the application area. The untreated partners not protected by clothing demonstrated low detectable plasma concentrations of Dridase (mean Cmax = 0.65 ng/mL). Only one of the 14 untreated subjects participating in the clothing-to-skin contact regimen had very low measurable Dridase plasma concentrations (Cmax = 0.06 ng/mL) during the 24 hours following contact with treated subjects; Dridase was not detectable with the remaining 13 untreated subjects. Regardless of the low exposure observed in this study, patients should avoid skin-to-skin contact with partners after applying the gel.
Use of Sunscreen
The effect of sunscreen on the absorption of Dridase when applied 30 minutes before or 30 minutes after Dridase 3% application was evaluated in a single-dose randomized crossover study (N = 20). Concomitant application of sunscreen, either before or after Dridase 3% application, had no effect on the systemic exposure of Dridase.
The effect of showering on the absorption of Dridase was evaluated in a randomized, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after Dridase 3% application (N = 22). The results of the study indicate that showering one hour after administration does not affect the overall systemic exposure to Dridase.
The effect of race on the pharmacokinetics of Dridase 3% has not been studied.
Available data suggest that there are no significant differences in the pharmacokinetics of Dridase based on geriatric status in patients following administration of Dridase 3% [see Use in Specific Populations (8.5) ].
The pharmacokinetics of Dridase and N-desethyloxybutynin following application of Dridase 3% has not been evaluated in individuals younger than 18 years of age [see Use in Specific Populations (8.4) ].
Available data suggest that there are no significant differences in the pharmacokinetics of Dridase based on gender in healthy volunteers following administration of Dridase 3%.
There is limited experience with the use of Dridase 3% in patients with renal insufficiency [see Use in Specific Populations (8.6) ].
There is limited experience with the use of Dridase 3% in patients with hepatic insufficiency [see Use in Specific Populations (8.7) ].
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
A 24-month study in rats at dosages of Dridase chloride of 20, 80, and 160 mg/kg showed no evidence of carcinogenicity. These doses are approximately 6, 25, and 50 times the maximum exposure in humans taking an oral dose, based on body surface area. Dridase chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae, and Salmonella typhimurium test systems. Reproduction studies with Dridase chloride in the mouse, rat, hamster, and rabbit showed no evidence of impaired fertility.
14 CLINICAL STUDIES
The efficacy and safety of Dridase 3% were evaluated in a single randomized, double-blind, placebo-controlled, multicenter 12-week study in patients with urinary frequency and urge and mixed urinary incontinence with a predominance of urge incontinence episodes. This was followed by an open-label safety extension. Key entry criteria included adults with overactive bladder (OAB) symptoms for at least 3 months who were either treatment-naïve or had demonstrated a beneficial response to anticholinergic treatment for OAB. Subjects were randomly assigned to receive 84 mg/day Dridase, 56 mg/day Dridase, or placebo. A total of 214 patients received 84 mg/day Dridase, 210 patients received 56 mg/day Dridase, and 202 patients received placebo gel. The majority of patients were Caucasian (87%) and female (87%), with a mean age of 59 years (range: 19 to 89 years). The primary efficacy endpoint was the change from baseline to week 12 in the number of urinary incontinence episodes (UIE) per week, as determined from a 3‑day patient daily diary.
Patients treated with Dridase 3% (84 mg) experienced a statistically significant decrease in the number of urinary incontinence episodes per week from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p = 0.0445) and patients treated with the 56 mg dose did not show statistically significant efficacy. Statistically significant improvements in daily urinary frequency (p = 0.0010) and urinary void volume (p < 0.0001) were also seen with Dridase 3% (84 mg) relative to placebo. The mean difference from placebo for Dridase 3% (84 mg) was -2.3 for urinary incontinence episodes per week in a group of patients with a mean of greater than 40 incontinence episodes per week at baseline. Mean and median change from baseline in weekly incontinence episodes (primary endpoint), daily urinary frequency, and urinary void volume (secondary endpoints) between placebo and Dridase 3% are summarized in Table 3.
¶ Last-Observation-Carried-Forward imputation for missing data
† P-value is based on ANCOVA analysis on rank-transformed data
‡ Comparison is significant if p ≤ 0.05
§ Comparison is significant if p ≤ 0.0125, adjusting for multiplicity
16 HOW SUPPLIED/STORAGE AND HANDLING
Dridase 3% (oxybutynin) gel 3% is supplied in a metered-dose pump dispenser composed of an inner aluminum laminated foil liner encased in a rigid plastic bottle with a plastic cap. The nozzle of the pump dispenser is sealed by a removable cap attached to the actuator by a plastic string.
NDC 52544-041-54 100 mL (92 g) metered pump dispenser containing 90 metered 0.92 g (1 mL) pumps delivering 28 mg Dridase per pump actuation.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). See USP controlled room temperature. Protect from moisture and humidity.
17 PATIENT COUNSELING INFORMATION
See FDA-approved patient labeling (Patient Information)
Instructions for Use
Inform patients of the following:
Important Anticholinergic Adverse Reactions
Patients should be informed that anticholinergic (antimuscarinic) agents, such as Dridase 3%, may produce clinically significant adverse reactions related to anticholinergic pharmacological activity. Heat prostration (due to decreased sweating) can occur when anticholinergics such as Dridase 3% are used in a hot environment. Because anticholinergic (antimuscarinic) agents, such as Dridase 3%, may produce dizziness or blurred vision, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until this product's effects have been determined. Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic (antimuscarinic) agents such as Dridase 3%.
For all medical inquiries contact:
Parsippany, NJ 07054
Actavis Pharma, Inc.
Parsippany, NJ 07054 USA
Content Updated: July 2015
FDA-approved patient labeling
Dridase [Gel-nēk] 3%
(oxybutynin) gel 3%
Important: For use on the skin only (topical). Do not get Dridase 3% in or near your eyes, nose, or mouth.
Read this Patient Information carefully before you use Dridase 3% and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
What is Dridase 3%?
Dridase 3% is a prescription medicine used to treat the symptoms of overactive bladder including:
It is not known if Dridase 3% is safe or effective in children.
Who should not use Dridase 3%?
Do not use Dridase 3% if:
Talk to your healthcare provider before taking this medicine if you have any of these conditions.
What should I tell my doctor before using Dridase 3%?
Before you use Dridase 3%, tell your doctor if you:
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.
Dridase 3% may affect the way other medicines work, and other medicines may affect how Dridase 3% works.
Especially tell your doctor if you take:
Ask your doctor if you are not sure if your medicine is one listed above.
Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.
How should I use Dridase 3%?
Dridase 3% is for skin use only.
How to use the Dridase 3% pump:
You must prime the pump before you use it for the first time.
To prime the pump:
Applying Dridase 3%:
1. Selecting your application site:
Apply Dridase 3% only to 1 of the shaded areas shown in the figure below:.
2. Dispensing your dose of Dridase 3%:
What should I avoid while using Dridase 3%?
What are the possible side effects of Dridase 3%?
The most common side effects of Dridase 3% include:
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Dridase 3%. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
How should I store Dridase 3%?
Keep Dridase 3% and all medicines out of the reach of children.
General information about the safe and effective use of Dridase 3%.
Medicines are sometimes prescribed for conditions that are not mentioned in the patient information leaflet. Do not use Dridase 3% for a condition for which it was not prescribed. Do not give Dridase 3% to other people, even if they have the same symptoms you have. It may harm them.
This Patient Information leaflet summarizes the most important information about Dridase 3%. If you would like more information about Dridase 3%, talk with your doctor. You can ask your pharmacist or doctor for information about Dridase 3% that is written for health professionals.
For more information go to www.gelnique.com or call 1-800-272-5525.
What are the ingredients in Dridase 3%?
Active ingredient: Dridase
Inactive ingredients: diethylene glycol monoethyl ether, NF; alcohol, USP; hydroxypropyl cellulose, NF; propylene glycol, NF; butylated hydroxytoluene, NF; HCl 0.1 M, NF; and purified water, USP.
This Patient Information has been approved by the U.S. Food and Drug Administration.
For all medical inquiries contact:
Parsippany, NJ 07054
Actavis Pharma, Inc.
Parsippany, NJ 07054 USA
Content Updated: January 2013
How to use the Dridase 3% pump Figure A Figure B Figure C
|With a meal||1||100.0%|
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Arunabha Ray, MD Pharmacology